

APPLICANT(S): NATHAN, Ilana et al.

SERIAL NO.: 10/509,405

FILED: September 24, 2004

Page 3

#### AMENDMENTS TO THE CLAIMS

Please add or amend the claims to read as follows, and cancel without prejudice or disclaimer to resubmission in a divisional or continuation application claims indicated as cancelled:

1. (Currently Amended) A method for inhibiting necrosis in neuronal, Purkinje, hippocampal, pyramidal or glial cells undergoing necrosis in a subject affected by Parkinson's Disease, or treating a neurodegenerative disorder associated with necrosis of said cells, comprising administering to the subject an elastase inhibiting agent that inhibits elastase activity within said cells, in an amount sufficient to inhibit necrosis of said cells, wherein said elastase inhibiting agent is capable of entering said cells.
2. (Cancelled)
3. (Currently Amended) The method according to claim 1, wherein the one or more elastase inhibiting agents administered cause administration of the elastase inhibiting agent to the subject causes partial conversion of necrosis to apoptosis, and wherein said method further comprises administration of an anti-apoptotic agent.
- 4-17. (Cancelled)
18. (Currently Amended) A method for treating cell necrosis in a subject in need thereof, comprising administering to a the subject in need one or more elastase inhibiting agents that inhibit elastase activity within the cells undergoing necrosis, in an amount sufficient to inhibit cell necrosis of said cells and cause partial conversion of necrosis to apoptosis, and wherein said method further comprises administration of an anti-apoptotic agent, wherein said amount of elastase inhibiting agent is less than the optimal amount for inhibiting necrosis when an anti-apoptotic agent is not used.
- 19-20 (Cancelled)
21. (Cancelled)